The IPO witnessed strong participation throughout investor classes: Certified Institutional Consumers (QIBs) subscribed 12.14 instances, retail buyers 10.54 instances, and Non-Institutional Traders (NIIs) 3.93 instances.
Accretion Prescription drugs, established in 2012, makes a speciality of manufacturing and advertising a various vary of pharmaceutical merchandise, together with tablets, capsules, oral liquids, exterior preparations, and oral powders.
With a presence in over 20 nations throughout Africa, Southeast Asia, and the Center East, Accretion has established itself as a major participant within the pharmaceutical sector.
Financially, the corporate has proven spectacular progress. For the fiscal 12 months 2024, Accretion reported a income of Rs 33.94 crore, up from Rs 29.53 crore within the earlier 12 months, and a revenue after tax of Rs 3.88 crore, a considerable improve from Rs 0.10 crore in FY23. These figures point out a robust upward trajectory in each income and profitability.
The proceeds from the IPO are earmarked for capital expenditures, together with the acquisition of recent gear and equipment, upgrading present manufacturing amenities, compensation of sure borrowings, funding working capital necessities, and basic company functions.Regardless of the robust fundamentals and investor curiosity, the absence of a gray market premium suggests a cautious strategy from the market, probably as a consequence of broader market circumstances or sector-specific components. Traders and market watchers will probably be keenly observing the inventory’s efficiency upon itemizing to gauge its reception within the public market.
